Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial

Mrinal M Gounder, Albiruni Abdul Razak, Neeta Somaiah, Sant Chawla, Javier Martin-Broto, Giovanni Grignani, Scott M Schuetze, Bruno Vincenzi, Andrew J Wagner, Bartosz Chmielowski, Robin L Jones, Richard F Riedel, Silvia Stacchiotti, Elizabeth T Loggers, Kristen N Ganjoo, Axel Le Cesne, Antoine Italiano, Xavier Garcia Del Muro, Melissa Burgess, Sophie Piperno-Neumann, Christopher Ryan, Mary F Mulcahy, Charles Forscher, Nicolas Penel, Scott Okuno, Anthony Elias, Lee Hartner, Tony Philip, Thierry Alcindor, Bernd Kasper, Peter Reichardt, Lore Lapeire, Jean-Yves Blay, Christine Chevreau, Claudia Maria Valverde Morales, Gary K Schwartz, James L Chen, Hari Deshpande, Elizabeth J Davis, Garth Nicholas, Stefan Gröschel, Helen Hatcher, Florence Duffaud, Antonio Casado Herráez, Roberto Diaz Beveridge, Giuseppe Badalamenti, Mikael Eriksson, Christian Meyer, Margaret von Mehren, Brian A Van Tine, Katharina Götze, Filomena Mazzeo, Alexander Yakobson, Aviad Zick, Alexander Lee, Anna Estival Gonzalez, Andrea Napolitano, Mark A Dickson, Dayana Michel, Changting Meng, Lingling Li, Jianjun Liu, Osnat Ben-Shahar, Dane R Van Domelen, Christopher J Walker, Hua Chang, Yosef Landesman, Jatin J Shah, Sharon Shacham, Michael G Kauffman, Steven Attia, Mrinal M Gounder, Albiruni Abdul Razak, Neeta Somaiah, Sant Chawla, Javier Martin-Broto, Giovanni Grignani, Scott M Schuetze, Bruno Vincenzi, Andrew J Wagner, Bartosz Chmielowski, Robin L Jones, Richard F Riedel, Silvia Stacchiotti, Elizabeth T Loggers, Kristen N Ganjoo, Axel Le Cesne, Antoine Italiano, Xavier Garcia Del Muro, Melissa Burgess, Sophie Piperno-Neumann, Christopher Ryan, Mary F Mulcahy, Charles Forscher, Nicolas Penel, Scott Okuno, Anthony Elias, Lee Hartner, Tony Philip, Thierry Alcindor, Bernd Kasper, Peter Reichardt, Lore Lapeire, Jean-Yves Blay, Christine Chevreau, Claudia Maria Valverde Morales, Gary K Schwartz, James L Chen, Hari Deshpande, Elizabeth J Davis, Garth Nicholas, Stefan Gröschel, Helen Hatcher, Florence Duffaud, Antonio Casado Herráez, Roberto Diaz Beveridge, Giuseppe Badalamenti, Mikael Eriksson, Christian Meyer, Margaret von Mehren, Brian A Van Tine, Katharina Götze, Filomena Mazzeo, Alexander Yakobson, Aviad Zick, Alexander Lee, Anna Estival Gonzalez, Andrea Napolitano, Mark A Dickson, Dayana Michel, Changting Meng, Lingling Li, Jianjun Liu, Osnat Ben-Shahar, Dane R Van Domelen, Christopher J Walker, Hua Chang, Yosef Landesman, Jatin J Shah, Sharon Shacham, Michael G Kauffman, Steven Attia

Abstract

Purpose: Antitumor activity in preclinical models and a phase I study of patients with dedifferentiated liposarcoma (DD-LPS) was observed with selinexor. We evaluated the clinical benefit of selinexor in patients with previously treated DD-LPS whose sarcoma progressed on approved agents.

Methods: SEAL was a phase II-III, multicenter, randomized, double-blind, placebo-controlled study. Patients age 12 years or older with advanced DD-LPS who had received two-five lines of therapy were randomly assigned (2:1) to selinexor (60 mg) or placebo twice weekly in 6-week cycles (crossover permitted). The primary end point was progression-free survival (PFS). Patients who received at least one dose of study treatment were included for safety analysis (ClinicalTrials.gov identifier: NCT02606461).

Results: Two hundred eighty-five patients were enrolled (selinexor, n = 188; placebo, n = 97). PFS was significantly longer with selinexor versus placebo: hazard ratio (HR) 0.70 (95% CI, 0.52 to 0.95; one-sided P = .011; medians 2.8 v 2.1 months), as was time to next treatment: HR 0.50 (95% CI, 0.37 to 0.66; one-sided P < .0001; medians 5.8 v 3.2 months). With crossover, no difference was observed in overall survival. The most common treatment-emergent adverse events of any grade versus grade 3 or 4 with selinexor were nausea (151 [80.7%] v 11 [5.9]), decreased appetite (113 [60.4%] v 14 [7.5%]), and fatigue (96 [51.3%] v 12 [6.4%]). Four (2.1%) and three (3.1%) patients died in the selinexor and placebo arms, respectively. Exploratory RNA sequencing analysis identified that the absence of CALB1 expression was associated with longer PFS with selinexor compared with placebo (median 6.9 v 2.2 months; HR, 0.19; P = .001).

Conclusion: Patients with advanced, refractory DD-LPS showed improved PFS and time to next treatment with selinexor compared with placebo. Supportive care and dose reductions mitigated side effects of selinexor. Prospective validation of CALB1 expression as a predictive biomarker for selinexor in DD-LPS is warranted.

Conflict of interest statement

Steven Attia

Research Funding: AB Science, Adaptimmune, Advenchen Laboratories, Bavarian Nordic, Bayer, Blueprint Medicines, BTG, CBA Pharma, CytRx Corporation, Daiichi Sankyo, Deciphera, Desmoid Tumor Research Foundation, Epizyme, FORMA Therapeutics, Genmab, GlaxoSmithKline, Gradalis, Immune Design, Incyte, Karyopharm Therapeutics, Lilly, Merck, Novartis, Philogen, PTC Therapeutics, Takeda, TRACON Pharma

Other Relationship: Immune Design

No other potential conflicts of interest were reported.

Figures

FIG 1.
FIG 1.
CONSORT diagram. AE, adverse event.
FIG 2.
FIG 2.
Efficacy by treatment arm. (A) Median progression-free survival. Kaplan-Meier curves by treatment arm. (B) Median OS. Kaplan-Meier curves by treatment arm. (C) Best overall response waterfall plots during blinded treatment: selinexor (upper panel) and placebo (lower panel). HR, hazard ratio; OS, overall survival; PD, progressive disease; PFS, progression-free survival; PR, partial response; SD, stable disease.
FIG 3.
FIG 3.
CALB1 expression is associated with selinexor resistance. (A) Flow diagram of patient samples that were sequenced. (B) Volcano plot showing the significance (y-axis) and fold-change (x-axis) of all genes compared between sensitive and resistant tumors in the set 1 comparison using RECIST tumor size change. (C) Expression of CALB1 in the set 1 tumor samples. (D) Significance and fold-change of all genes in the set 2 comparison of patients with favorable and poor PFS. (E) Expression of CALB1 in set 2. (F) CT scans from a patient who had a mesentery lesion that steadily reduced in size over 4 months after starting selinexor treatment on SEAL and then remained stable. A scan on day 251 revealed a small nodule that rapidly grew while the patient continued selinexor treatment, until both tumors were resected on day 349. (G) PFS of phase III selinexor and placebo arm patients restricted to those patients without detectable CALB1. (H and I) PFS of phase III (H) selinexor or (I) placebo arm patients stratified by CALB1 expression. Shaded areas represent 95% CIs. HR, hazard ratio; PFS, progression-free survival; PR, partial response.

References

    1. Crago AM, Singer S: Clinical and molecular approaches to well differentiated and dedifferentiated liposarcoma. Curr Opin Oncol 23:373-378, 2011
    1. Thomas DM, Conyers R, Young S: Liposarcoma: Molecular genetics and therapeutics. Sarcoma 2011:483154, 2011
    1. Livingston JA, Bugano D, Barbo A, et al. : Role of chemotherapy in dedifferentiated liposarcoma of the retroperitoneum: Defining the benefit and challenges of the standard. Sci Rep 7:1-8, 2017
    1. Italiano A, Toulmonde M, Cioffi A, et al. : Advanced well-differentiated/dedifferentiated liposarcomas: Role of chemotherapy and survival. Ann Oncol 23:1601-1607, 2012
    1. Jones RL, Fisher C, Al-Muderis O, et al. : Differential sensitivity of liposarcoma subtypes to chemotherapy. Eur J Cancer 41:2853-2860, 2005
    1. Stacchiotti S, Van der Graaf W, Doms H, et al. : 1629MO—First-line chemotherapy (CT) in advanced well-differentiated/dedifferentiated liposarcoma (WD/DD LPS): An EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis. Ann Oncol 31:S978, 2020
    1. Demetri GD, Von Mehren M, Jones RL, et al. : Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: Results of a phase III randomized multicenter clinical trial. J Clin Oncol 34:786-793, 2016
    1. Demetri GD, Schöffski P, Grignani G, et al. : Activity of eribulin in patients with advanced liposarcoma demonstrated in a subgroup analysis from a randomized phase III study of eribulin versus dacarbazine. J Clin Oncol 35:3433-3439, 2017
    1. Ricciotti RW, Baraff AJ, Jour G, et al. : High amplification levels of MDM2 and CDK4 correlate with poor outcome in patients with dedifferentiated liposarcoma: A cytogenomic microarray analysis of 47 cases. Cancer Genet 218–219:69-80, 2017
    1. Bill KLJ, Seligson ND, Hays JL, et al. : Degree of MDM2 amplification affects clinical outcomes in dedifferentiated liposarcoma. Oncologist 24:989-996, 2019
    1. Singer S, Socci ND, Ambrosini G, et al. : Gene expression profiling of liposarcoma identifies distinct biological types/subtypes and potential therapeutic targets in well-differentiated and dedifferentiated liposarcoma. Cancer Res 67:6626-6636, 2007
    1. Nie L, Sasaki M, Maki CG: Regulation of p53 nuclear export through sequential changes in conformation and ubiquitination. J Biol Chem 282:14616-14625, 2007
    1. Garg M, Kanojia D, Mayakonda A, et al. : Molecular mechanism and therapeutic implications of selinexor (KPT-330) in liposarcoma. Oncotarget 8:7521-7532, 2017
    1. Kalakonda N, Maerevoet M, Cavallo F, et al. : Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): A single-arm, multinational, multicentre, open-label, phase 2 trial. Lancet Haematol 7:e511-e522, 2020
    1. Ben-Barouch S, Kuruvilla J: Selinexor (KTP-330)—A selective inhibitor of nuclear export (SINE): Anti-tumor activity in diffuse large B-cell lymphoma (DLBCL). Expert Opin Investig Drugs 29:15-21, 2020
    1. Abdul Razak AR, Mau-Soerensen M, Gabrail NY, et al. : First-in-class, first-in-human phase I study of selinexor, a selective inhibitor of nuclear export, in patients with advanced solid tumors. J Clin Oncol 34:4142-4150, 2016
    1. Nakayama R, Zhang YX, Czaplinski JT, et al. : Preclinical activity of selinexor, an inhibitor of XPO1, in sarcoma. Oncotarget 7:16581-16592, 2016
    1. Gounder MM, Zer A, Tap WD, et al. : Phase IB study of selinexor, a first-in-class inhibitor of nuclear export, in patients with advanced refractory bone or soft tissue sarcoma. J Clin Oncol 34:3166-3174, 2016
    1. Nair JS, Musi E, Schwartz GK: Selinexor (KPT-330) induces tumor suppression through nuclear sequestration of IκB and downregulation of survivin. Clin Cancer Res 23:4301-4311, 2017
    1. Grosicki S, Simonova M, Spicka I, et al. : Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): A randomised, open-label, phase 3 trial. Lancet 396:1563-1573, 2020
    1. Chari A, Vogl DT, Gavriatopoulou M, et al. : Oral selinexor–dexamethasone for triple-class refractory multiple myeloma. N Engl J Med 381:727-738, 2019
    1. Nair JS, Tap W, Vasudeva SD, et al. : Abstract 5210: KPT-330, a selective small molecule inhibitor of nuclear export, is active in bone and soft tissue sarcoma. Cancer Research. American Association for Cancer Research (AACR), 2013, pp 5210
    1. Crochiere ML, Kashyap T, Klebanov B, et al. : Abstract 3810: Selinexor (KPT-330), a novel selective inhibitor of nuclear export (SINE), shows single agent efficacy against alveolar soft part sarcoma (ASPS) in vivo. Cancer Research. American Association for Cancer Research (AACR), 2014, pp 3810
    1. US Department of Health and Human Services: National Institutes of Health and National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE). Version 4.3, 2010 .
    1. Cancer Genome Atlas Research Network : Comprehensive and integrated genomic characterization of adult soft tissue sarcomas. Cell 171:950-965, 2017
    1. Bock S, Hoffmann DG, Jiang Y, et al. : Increasing incidence of liposarcoma: A population-based study of national surveillance databases, 2001–2016. Int J Environ Res Public Health 17:2710, 2020
    1. Dickson MA, Schwartz GK, Keohan ML, et al. : Phase 2 trial of the CDK4 inhibitor palbociclib (PD0332991) at 125 mg dose in well-differentiated or dedifferentiated liposarcoma. JAMA Oncol 2:937, 2016
    1. Dickson MA, Tap WD, Keohan ML, et al. : Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma. J Clin Oncol 31:2024-2028, 2013
    1. Dickson MA, Koff A, D’Angelo SP, et al. : Phase 2 study of the CDK4 inhibitor abemaciclib in dedifferentiated liposarcoma. J Clin Oncol 37, 2019. (suppl; abstr 11004)
    1. Gounder MM, Bauer TM, Schwartz GK, et al. : Milademetan, an oral MDM2 inhibitor, in well-differentiated/dedifferentiated liposarcoma: Results from a phase 1 study in patients with solid tumors or lymphomas. Eur J Cancer 138:S3-S4, 2020
    1. Gounder M, Abdul Razak AR, Gilligan AM, et al. : Health-related quality of life and pain with selinexor in patients with advanced dedifferentiated liposarcoma. Futur Oncol 17:2923-2939, 2021
    1. McDonough J, Eliott J, Neuhaus S, et al. : Health-related quality of life, psychosocial functioning, and unmet health needs in patients with sarcoma: A systematic review. Psychooncology 28:653-664, 2019
    1. Rhoten WB, Bruns ME, Christakos S: Presence and localization of two vitamin D-dependent calcium binding proteins in kidneys of higher vertebrates. Endocrinology 117:674-683, 1985
    1. Cao LQ, Wang YN, Liang M, et al. : CALB1 enhances the interaction between p53 and MDM2, and inhibits the senescence of ovarian cancer cells. Mol Med Rep 19:5097-5104, 2019
    1. Pelc K, Vincent S, Ruchoux MM, et al. : Calbindin-D28k: A marker of recurrence for medulloblastomas. Cancer 95:410-419, 2002

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj